search
Back to results

In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases (MuTreg)

Primary Purpose

Autoimmune Diseases, Inflammatory Disease, Acquired Bone Marrow Aplasia

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Blood sample taken at a single time point
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional basic science trial for Autoimmune Diseases focused on measuring Autoimmune Diseases, Inflammation, Graft vs Host Disease, T-lymphocytes, Regulatory, Interleukin-2

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Inclusion criteria common to all patients in different departments:
  • Age18 years
  • Affiliated to social security or entitled to
  • Patient who has been informed of the study and has signed a free and informed consent

Inclusion criteria specific by department:

Inclusion criteria for Clinical Hematology Department:

  • Patient with GVHD following allogeneic hematopoietic stem cell transplantation (HSC)
  • Or with acquired bone marrow suppression
  • Lymphocytosis > 0.5 G/L

Inclusion criteria for Nephrology and Transplantation department:

- Patient with systemic lupus erythematosus (ACR classification criteria)

Inclusion criteria for Neurology department:

- Patient with multiple sclerosis (criteria of Mc Donald 2017)

Inclusion criteria for Rheumatology Department:

- Patient with rheumatoid arthritis (ACR classification criteria)

Inclusion criteria for Internal Medicine-Endocrinology Department:

- Patient with Basedow disease, Hashimoto's thyroiditis

Inclusion criteria for Dermatology Department:

- Patient with vitiligo or alopecia areata or atopic dermatitis

Exclusion Criteria:

Non-inclusion criteria common to all patients:

  • Patient under guardianship, curatorship or judicial protection
  • Pregnant, parturient or breastfeeding woman
  • Patient deprived of liberty
  • Patient hospitalized without consent
  • Patient admitted to a health or social institution for purposes other than research
  • Minor patient
  • Adult patient unable to express consent
  • Refusal to participate
  • Patient on AME

Non-inclusion criteria specific by department:

Non-inclusion criteria for Clinical Hematology Department:

  • Ongoing treatment with high doses (>1 mg/kg/d) of systemic corticosteroid therapy
  • Ongoing treatment with JAK inhibitors

Non-inclusion criteria for Nephrology and Transplantation Department:

  • Ongoing treatment with doses >10 mg/d Prednisone
  • Ongoing treatment with Cellcept, Endoxan, Imurel, Belimumab, Anti-CD20, Methotrexate
  • Ongoing treatment with JAK inhibitors

Non-inclusion criteria for Neurology Department:

  • Treatment with systemic corticosteroid therapy, Fingolimod or Teriflunomide
  • Ongoing treatment with JAK inhibitors
  • Lymphocytosis < 0.5 G/L

Non-inclusion criteria for Rheumatology Department:

  • Ongoing treatment with doses >15 mg/d Prednisone
  • Treatment with Rituximab or Tocilizumab
  • Ongoing treatment with JAK inhibitors
  • Lymphocytosis < 0.5 G/L

Non-inclusion criteria for Internal Medicine - Endocrinology Department:

  • Ongoing immunosuppressive therapy
  • Ongoing treatment with JAK inhibitors

Non-inclusion criteria for Dermatology Department:

  • Ongoing treatment with Methotrexate
  • Ongoing treatment with JAK inhibitors
  • Ongoing treatment with doses >10 mg/d prednisone

Sites / Locations

    Outcomes

    Primary Outcome Measures

    the percentage of phosphorylated STAT5 in LTresg compared to LTconv after incubation with IL-2 muteins
    The measurement method is based on the quantification of the phosphorylated STAT5 molecule in LTconv and LTreg by flow cytometry after incubating the cells with IL-2 or IL-2 muteins

    Secondary Outcome Measures

    Full Information

    First Posted
    September 14, 2022
    Last Updated
    September 14, 2022
    Sponsor
    Assistance Publique - Hôpitaux de Paris
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05544448
    Brief Title
    In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases
    Acronym
    MuTreg
    Official Title
    n Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    September 2022
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    October 15, 2022 (Anticipated)
    Primary Completion Date
    April 15, 2023 (Anticipated)
    Study Completion Date
    April 15, 2023 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Assistance Publique - Hôpitaux de Paris

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Interleukin 2 (IL-2) is a critical cytokine for the survival and function of regulatory T cells (LTreg). This cytokine has a dual role in the immune system. IL-2 stimulates immune responses by acting on the intermediate affinity IL-2R receptor, IL-2Rβγ, expressed by conventional T cells (LTconv) during activation, but also contributes to the inhibition of immune responses via LTreg that express the high affinity receptor IL-2Rαβγ. This difference in IL-2 receptor affinity for IL-2 has led to the development of low-dose IL-2 therapy to stimulate LTreg and improve control of excessive inflammation in autoimmune (AID), inflammatory or alloimmune diseases Low-dose IL-2 therapy is being studied in several of these diseases such as systemic lupus erythematosus, type 1 diabetes, alopecia, HCV (hepatitis C virus)-induced vasculitis, atopic dermatitis and chronic allo-transplantation-related graft-versus-host disease (GVHD). Some of these studies have shown an increase in LTreg numbers and an improvement in certain clinical signs. To improve LTreg targeting in autoimmune diseases, inflammatory diseases or GVHD, mutated IL-2s (muteins) have been developed with selective LTreg agonist properties. These IL-2 muteins are linked to an Fc fragment to increase their half-life. Two IL-2 variants (IL-2Vs)-Fc preferentially stimulate STAT5 phosphorylation in LTregs compared to conventional FoxP3- (LTconv) CD4+ or CD8+ T cells
    Detailed Description
    Hypothesis: In order to confirm that this differential effect of IL-2 muteins, already established in non-diseased controls, is also observed in patients with autoimmune diseases, inflammatory diseases or GVHD, a pilot in vitro study should be conducted on a small number of patient's blood samples (5 or 10 depending on the pathology). Objective : Conduct a multicentre pilot study to confirm the hypothesis that IL-2 muteins preferentially activate the STAT5 pathway in LTreg compared to LTconv in patients with GVHD, acquired bone marrow aplasia, systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, autoimmune thyroiditis, vitiligo, alopecia or atopic dermatitis Method: At the inclusion, patients will have a blood sample collected for in vitro research purposes. Their clinical data will also be collected. Conclusion This trial should provide in vitro proof-of-principle of the efficacy of IL-2 muteins on LTreg and could eventually lead to a therapeutic trial

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Autoimmune Diseases, Inflammatory Disease, Acquired Bone Marrow Aplasia, Systemic Lupus Erythematosus, Multiple Sclerosis, Gvhd, Rheumatoid Arthritis, Autoimmune Thyroiditis, Vitiligo, Alopecia, Atopic Dermatitis
    Keywords
    Autoimmune Diseases, Inflammation, Graft vs Host Disease, T-lymphocytes, Regulatory, Interleukin-2

    7. Study Design

    Primary Purpose
    Basic Science
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Model Description
    This study is a multicenter, open-label, non-controlled, non-randomized in vitro study.
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    90 (Anticipated)

    8. Arms, Groups, and Interventions

    Intervention Type
    Other
    Intervention Name(s)
    Blood sample taken at a single time point
    Intervention Description
    At inclusion, a blood sample will be taken for research purpose
    Primary Outcome Measure Information:
    Title
    the percentage of phosphorylated STAT5 in LTresg compared to LTconv after incubation with IL-2 muteins
    Description
    The measurement method is based on the quantification of the phosphorylated STAT5 molecule in LTconv and LTreg by flow cytometry after incubating the cells with IL-2 or IL-2 muteins
    Time Frame
    At inclusion

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Inclusion criteria common to all patients in different departments: Age18 years Affiliated to social security or entitled to Patient who has been informed of the study and has signed a free and informed consent Inclusion criteria specific by department: Inclusion criteria for Clinical Hematology Department: Patient with GVHD following allogeneic hematopoietic stem cell transplantation (HSC) Or with acquired bone marrow suppression Lymphocytosis > 0.5 G/L Inclusion criteria for Nephrology and Transplantation department: - Patient with systemic lupus erythematosus (ACR classification criteria) Inclusion criteria for Neurology department: - Patient with multiple sclerosis (criteria of Mc Donald 2017) Inclusion criteria for Rheumatology Department: - Patient with rheumatoid arthritis (ACR classification criteria) Inclusion criteria for Internal Medicine-Endocrinology Department: - Patient with Basedow disease, Hashimoto's thyroiditis Inclusion criteria for Dermatology Department: - Patient with vitiligo or alopecia areata or atopic dermatitis Exclusion Criteria: Non-inclusion criteria common to all patients: Patient under guardianship, curatorship or judicial protection Pregnant, parturient or breastfeeding woman Patient deprived of liberty Patient hospitalized without consent Patient admitted to a health or social institution for purposes other than research Minor patient Adult patient unable to express consent Refusal to participate Patient on AME Non-inclusion criteria specific by department: Non-inclusion criteria for Clinical Hematology Department: Ongoing treatment with high doses (>1 mg/kg/d) of systemic corticosteroid therapy Ongoing treatment with JAK inhibitors Non-inclusion criteria for Nephrology and Transplantation Department: Ongoing treatment with doses >10 mg/d Prednisone Ongoing treatment with Cellcept, Endoxan, Imurel, Belimumab, Anti-CD20, Methotrexate Ongoing treatment with JAK inhibitors Non-inclusion criteria for Neurology Department: Treatment with systemic corticosteroid therapy, Fingolimod or Teriflunomide Ongoing treatment with JAK inhibitors Lymphocytosis < 0.5 G/L Non-inclusion criteria for Rheumatology Department: Ongoing treatment with doses >15 mg/d Prednisone Treatment with Rituximab or Tocilizumab Ongoing treatment with JAK inhibitors Lymphocytosis < 0.5 G/L Non-inclusion criteria for Internal Medicine - Endocrinology Department: Ongoing immunosuppressive therapy Ongoing treatment with JAK inhibitors Non-inclusion criteria for Dermatology Department: Ongoing treatment with Methotrexate Ongoing treatment with JAK inhibitors Ongoing treatment with doses >10 mg/d prednisone
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Philippe REMY, MD
    Phone
    01 49 81 24 59
    Ext
    33
    Email
    Philippe.remy@aphp.fr
    First Name & Middle Initial & Last Name or Official Title & Degree
    José Cohen, PHD
    Phone
    01 49 81 44 75
    Ext
    33
    Email
    jose.cohen@inserm.fr

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases

    We'll reach out to this number within 24 hrs